Ore Pharmaceuticals is a drug development and indication discovery company. We utilize proprietary capabilities in integrative pharmacology to identify new uses for drugs and drug candidates. Our goal is to enrich pharmaceutical pipelines by supplying the industry's demand for development-stage drug compounds. We do this in two ways: we identify new uses for stalled or failed drug compounds provided by our pharmaceutical partners. And we also identify new uses for drug compounds acquired from the public domain.
We use our Indication-Seeking Program and Drug Development Pipeline to quickly and efficiently reposition high-quality compounds and get them back into the pipeline so they can provide a rapid return on their initial investment.
How are we doing so far? Ore Pharmaceuticals has initiated the evaluation of more than 100 compounds provided by our pharmaceutical company partners. And we are ready to out-license the first drug from our own development pipeline: GL1001, a late-stage compound originally developed for obesity which we have identified and validated for inflammatory bowel disease (IBD) and other gastrointestinal disorders.